Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Medicine
Published in: Clinical and Experimental Medicine 3/2010

01-09-2010 | Original Article

Comparison of tuberculin skin test and QuantiFERON-TB gold in tube test in patients with chronic inflammatory diseases living in a tuberculosis endemic population

Authors: Feride Gogus, Zafer Günendi, Resul Karakus, Zeynep Erdogan, Kenan Hizel, Fatma Atalay

Published in: Clinical and Experimental Medicine | Issue 3/2010

Login to get access

Abstract

We aimed to compare tuberculin skin test (TST) and QuantiFERON-TB gold in tube (QFT-IT) in patients with chronic inflammatory diseases living in a population where tuberculosis is endemic and BCG vaccination is routine. Twenty-five patients with rheumatoid arthritis (RA), 16 patients with spondilarthropathy (SpA) and 7 healthy volunteers were recruited in the study. Blood samples were collected for QFT-IT test followed by TST. TST was considered to be positive with an enduration of 5 mm and over in patients with RA and SpA. The cutoff point for TST for the healthy control (HC) was 10 mm. Median TST result of patients who were using immunosuppressive drugs was significantly lower than that of patients who were not [5 (14.5), 13.5 (9.5), respectively, P = 0.04]. Poor agreement between TST and QFT-IT was seen in patients with RA (κ = 0.141) and in patients with SpA (κ = 0.190). We found poor concordance between QFT-IT and TST in patients with chronic inflammatory diseases, and TST response was suppressed in patients treated with immunosuppressive drugs.
Literature
1.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104CrossRefPubMed
2.
Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122–2127CrossRefPubMed
3.
Menzies D, Pai M, Comstock G (2007) Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146:340–354PubMed
4.
Huebner RE, Schein MF, Bass JB Jr (1993) The tuberculin skin test. Clin Infect Dis 17:968–975PubMed
5.
Nizam S, Emery P (2006) Attenuated response to purified protein derivative in patients with rheumatoid arthritis. Ann Rheum Dis 65:980CrossRefPubMed
6.
Emery P, Panayi G, Symmons D, Brown G (1984) Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: the role of protein energy malnutrition. Ann Rheum Dis 43:430–434CrossRefPubMed
7.
Ferrara G, Losi M, D’Amico R et al (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367:1328–1334CrossRefPubMed
8.
Mori T, Sakatani M, Yamagishi F et al (2004) Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 170:59–64CrossRefPubMed
9.
Mazurek GH, Jereb J, Lobue P et al (2005) Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54:49–55PubMed
10.
Markusse HM, Hazes JM, Dijkmans BA, de Vries RR, Stanford JL (1988) Skin test responsiveness to Mycobacterium tuberculosis, HLA-DR4, and rheumatoid arthritis. Br J Rheumatol 27:409–411PubMed
11.
Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A et al (2005) Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 64:1360–1361CrossRefPubMed
12.
Efthimiou P, Sood S (2007) QuantiFERON TB Gold Test: the new standard for screening of latent tuberculosis in patients with rheumatoid arthritis? Ann Rheum Dis 66:276CrossRefPubMed
13.
Pratt A, Nicholl K, Kay L (2007) Use of the QuantiFERON TB gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience. Rheumatology (Oxford) 46:1035–1036CrossRef
14.
Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL (2008) Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 59:800–806CrossRefPubMed
15.
Matulis G, Jüni P, Villiger PM, Gadola SD (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 67:84–90CrossRefPubMed
16.
Detjen AK, Keil T, Roll S, Hauer B, Mauch H, Wahn U, Magdorf K (2007) Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis 45:322–328CrossRefPubMed
17.
Ozdemir D, Annakkaya AN, Tarhan G, Sencan I, Cesur S, Balbay O, Guclu E (2007) Comparison of the tuberculin skin test and the QuantiFERON test for latent Mycobacterium tuberculosis infections in health care workers in Turkey. Jpn J Infect Dis 60:102–105PubMed
18.
Takahashi H, Shigehara K, Yamamoto M et al (2007) Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int 27:1143–1148CrossRefPubMed
19.
Pai M, Gokhale K, Joshi R et al (2005) Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing. JAMA 293:2746–2755CrossRefPubMed
20.
Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, Yim JJ (2005) Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 293:2756–2761CrossRefPubMed
21.
Harada N, Nakajima Y, Higuchi K, Sekiya Y, Rothel J, Mori T (2006) Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese healthcare workers. Infect Control Hosp Epidemiol 27:442–448CrossRefPubMed
22.
Diel R, Nienhaus A, Lange C, Meywald-Walter K, Forssbohm M, Schaberg T (2006) Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir Res 7:77CrossRefPubMed
23.
Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S et al (2008) Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 35:776–781PubMed
24.
Ferrara G, Losi M, Meacci M et al (2005) Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 172:631–635CrossRefPubMed
25.
Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P (2006) Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res 7:56CrossRefPubMed
26.
Kobashi Y, Mouri K, Obase Y, Fukuda M, Miyashita N, Oka M (2007) Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J 30:945–950CrossRefPubMed
27.
Hamdi H, Mariette X, Godot V et al (2006) Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8:R114CrossRefPubMed
Metadata
Title
Comparison of tuberculin skin test and QuantiFERON-TB gold in tube test in patients with chronic inflammatory diseases living in a tuberculosis endemic population
Authors
Feride Gogus
Zafer Günendi
Resul Karakus
Zeynep Erdogan
Kenan Hizel
Fatma Atalay
Publication date
01-09-2010
Publisher
Springer Milan
Published in
Clinical and Experimental Medicine / Issue 3/2010
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-009-0082-9

Other articles of this Issue 3/2010

Clinical and Experimental Medicine 3/2010 Go to the issue

Original Article

Effects of cigarette smoke extract on A549 cells and human lung fibroblasts treated with transforming growth factor-β1 in a coculture system

Original Article

The metabolic profile in patients with skin tags

Short Communication

Regulation of mRNA caspase-8 levels by anti-nuclear autoantibodies

Original Article

Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women

Original Article

DNA methylation and not allelic variation regulates STAT6 expression in human T cells

Original Article

VEGF-A/HGF induce Prox-1 expression in the chick embryo chorioallantoic membrane lymphatic vasculature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits